BRPI1008035A2 - anticorpos contendo peptídeos terapêuticos miméticos de tpo/epo - Google Patents

anticorpos contendo peptídeos terapêuticos miméticos de tpo/epo

Info

Publication number
BRPI1008035A2
BRPI1008035A2 BRPI1008035A BRPI1008035A BRPI1008035A2 BR PI1008035 A2 BRPI1008035 A2 BR PI1008035A2 BR PI1008035 A BRPI1008035 A BR PI1008035A BR PI1008035 A BRPI1008035 A BR PI1008035A BR PI1008035 A2 BRPI1008035 A2 BR PI1008035A2
Authority
BR
Brazil
Prior art keywords
antibodies containing
therapeutic peptides
epo mimetic
containing tpo
mimetic therapeutic
Prior art date
Application number
BRPI1008035A
Other languages
English (en)
Inventor
Gies David
P Springhorn Jeremy
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Publication of BRPI1008035A2 publication Critical patent/BRPI1008035A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BRPI1008035A 2009-02-24 2010-02-18 anticorpos contendo peptídeos terapêuticos miméticos de tpo/epo BRPI1008035A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20848709P 2009-02-24 2009-02-24
PCT/US2010/024546 WO2010099019A1 (en) 2009-02-24 2010-02-18 Antibodies containing therapeutic tpo/epo mimetic peptides

Publications (1)

Publication Number Publication Date
BRPI1008035A2 true BRPI1008035A2 (pt) 2017-03-21

Family

ID=42665848

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1008035A BRPI1008035A2 (pt) 2009-02-24 2010-02-18 anticorpos contendo peptídeos terapêuticos miméticos de tpo/epo

Country Status (14)

Country Link
US (1) US9493551B2 (pt)
EP (2) EP2401302A4 (pt)
JP (2) JP2012518408A (pt)
KR (1) KR20110122846A (pt)
CN (1) CN102428105B (pt)
AU (1) AU2010218277B2 (pt)
BR (1) BRPI1008035A2 (pt)
CA (1) CA2753438A1 (pt)
IL (1) IL214714A0 (pt)
MX (1) MX2011008936A (pt)
NZ (2) NZ594638A (pt)
RU (1) RU2559526C2 (pt)
SG (1) SG173680A1 (pt)
WO (1) WO2010099019A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2192842A1 (en) * 2007-09-18 2010-06-09 Novozymes A/S Method for producing an acidified milk drink
WO2012121958A2 (en) * 2011-03-08 2012-09-13 Glaxosmithkline Llc Combination
CN105658670A (zh) * 2013-08-21 2016-06-08 乌雷卡有限公司 肽-低聚尿素嵌合化合物及其使用方法
US10385209B2 (en) * 2014-12-09 2019-08-20 Denka Company Limited Polyamide-based fiber for artificial hair having exceptional dripping resistance upon combustion
KR20210016479A (ko) 2015-12-04 2021-02-15 노파르티스 아게 항체 시토카인 그라프트된 조성물 및 면역조절을 위한 사용 방법
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
WO2018222901A1 (en) * 2017-05-31 2018-12-06 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
EP3658191A1 (en) * 2017-07-26 2020-06-03 Janssen Pharmaceutica NV Methods of protecting vascular integrity induced by targeted radiation therapy
WO2020209920A2 (en) * 2019-01-25 2020-10-15 Janssen Pharmaceutica Nv Methods of mitigating toxic effects of vesicants and caustic gas
MA54820A (fr) * 2019-01-25 2021-12-01 Janssen Pharmaceutica Nv Méthodes d'atténuation d'une lésion hépatique et de promotion d'une hypertrophie hépatique, de régénération du foie et de prise de greffe de cellules hépatiques conjointement avec des traitements par radiothérapie et/ou radiomimétiques
US11723888B2 (en) 2021-12-09 2023-08-15 Nanopharmaceuticals Llc Polymer conjugated thyrointegrin antagonists
CN117986346A (zh) * 2024-04-07 2024-05-07 中国人民解放军军事科学院军事医学研究院 一种tpo模拟肽及其应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
AU6131086A (en) 1985-07-05 1987-01-30 Whitehead Institute For Biomedical Research Epithelial cells expressing foreign genetic material
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
WO1989002468A1 (en) 1987-09-11 1989-03-23 Whitehead Institute For Biomedical Research Transduced fibroblasts and uses therefor
DE3851153T2 (de) 1987-12-11 1995-01-05 Whitehead Biomedical Inst Genetische modifizierung von endothelialen zellen.
JP2917998B2 (ja) 1988-02-05 1999-07-12 ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ 修飾された肝細胞およびその用途
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
WO1992007943A1 (en) 1990-10-31 1992-05-14 Somatix Therapy Corporation Retroviral vectors useful for gene therapy
KR0185215B1 (ko) 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
US5830851A (en) 1993-11-19 1998-11-03 Affymax Technologies N.V. Methods of administering peptides that bind to the erythropoietin receptor
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
EP2055712A1 (en) 1995-06-07 2009-05-06 Glaxo Group Limited Peptides and compounds that bind to a thrombopoietin receptor
JP2000507575A (ja) 1996-03-29 2000-06-20 ジー.ディー.サール アンド カンパニー シクロプロピルアルカノイック酸誘導体
US5835382A (en) 1996-04-26 1998-11-10 The Scripps Research Institute Small molecule mimetics of erythropoietin
AU3117697A (en) 1996-05-06 1997-11-26 Uab Research Foundation, The Radiolabeled fusion toxins for cancer therapy
US7056897B2 (en) 1997-11-03 2006-06-06 The Arizona Board Of Regents Inducible expression vectors and methods of use thereof
CA2380331C (en) * 1999-08-09 2012-11-20 Lexigen Pharmaceuticals Corp. Multiple cytokine-antibody complexes
US7091396B1 (en) 2000-10-17 2006-08-15 The Rockefeller University Animals, cells and methods for production of detectably-labeled antibodies
US20040253242A1 (en) * 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
US7396917B2 (en) * 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
DK1642910T3 (da) * 2000-12-05 2012-05-07 Alexion Pharma Inc Rationelt designede atistoffer
FR2849436B1 (fr) 2002-12-27 2007-01-05 Patrick Frayssinet Particules et ceramiques de phosphates de calcium pour transfection in vivo et in vitro
US20070275871A1 (en) * 2003-08-28 2007-11-29 Biorexis Technology, Inc. Epo Mimetic Peptides and Fusion Proteins
CN1890383A (zh) * 2003-09-30 2007-01-03 森托科尔公司 人铰链核心模拟体、组合物、方法和用途
UA89481C2 (uk) * 2003-09-30 2010-02-10 Центокор, Инк. Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
EA011879B1 (ru) * 2004-09-24 2009-06-30 Эмджин Инк. МОЛЕКУЛЫ С МОДИФИЦИРОВАННЫМ Fc ФРАГМЕНТОМ
WO2007048022A2 (en) 2005-10-21 2007-04-26 Alexion Pharmaceuticals, Inc. Antibody-polypeptide fusion proteins and methods for producing and using same
US7625564B2 (en) 2006-01-27 2009-12-01 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
WO2007115148A2 (en) * 2006-03-31 2007-10-11 Centocor, Inc. Human mimetic epo hinge core mimetibodies

Also Published As

Publication number Publication date
SG173680A1 (en) 2011-09-29
AU2010218277A1 (en) 2011-09-08
RU2011139129A (ru) 2013-04-10
US9493551B2 (en) 2016-11-15
EP2401302A1 (en) 2012-01-04
RU2559526C2 (ru) 2015-08-10
EP2752427A1 (en) 2014-07-09
JP2012518408A (ja) 2012-08-16
NZ603712A (en) 2014-05-30
NZ594638A (en) 2013-03-28
JP2015043783A (ja) 2015-03-12
US20120070434A1 (en) 2012-03-22
KR20110122846A (ko) 2011-11-11
IL214714A0 (en) 2011-11-30
CN102428105A (zh) 2012-04-25
EP2401302A4 (en) 2013-10-09
WO2010099019A1 (en) 2010-09-02
CN102428105B (zh) 2015-09-30
MX2011008936A (es) 2011-09-21
AU2010218277B2 (en) 2014-07-17
CA2753438A1 (en) 2010-09-02

Similar Documents

Publication Publication Date Title
BRPI1008035A2 (pt) anticorpos contendo peptídeos terapêuticos miméticos de tpo/epo
EP2448972A4 (en) IMMUNOGLOBULIN FC POLYPEPTIDES
SI2949666T1 (sl) Človeška anti alfa-sinukleinska protitelesa
BRPI1011005A2 (pt) anticorpos anti-epcam
PL2262831T4 (pl) Przeciwciała przeciwko properdynie
IL236236A (en) Antibodies to the fam26f polypeptide
EP2207803A4 (en) CD9-SPECIFIC HUMAN ANTIBODIES
BRPI0915367A2 (pt) peptídeos e epítopos anti-p2x7
BRPI0915718A2 (pt) peptídeos de direção crkl
BRPI0922716A2 (pt) purificação de polipeptídeo
GB0920981D0 (en) Peptides
GB0815788D0 (en) Therapeutic antibodies
IL212078A0 (en) Antibodies to modified human igf-1/e peptides
IL240134A0 (en) new proteins
EP2324059A4 (en) THERAPEUTIC ANTI-PAMP ANTIBODIES
IT1395137B1 (it) Nuovi peptidi antipatogeni
EP2254901A4 (en) THERAPEUTIC PEPTIDES
EP2484694A4 (en) MONOCLONAL ANTIBODY AGAINST HUMAN H1G1 POLYPEPTIDE
GB0920987D0 (en) Peptides
HRP20190159T1 (hr) Antitijela humanog anti-alfa-sinukleina
GB0817978D0 (en) Peptides
EP2264057A4 (en) RECOMBINANT ANTIGEN
UA18028S (uk) Кришка до пляшки
GB0815673D0 (en) Peptides
GB0812093D0 (en) Phylloseptin peptides

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]